Sleep Trial to Prevent Alzheimer's Disease

Phase 2

Recruiting

• Conditions: Sleep; Alzheimer Disease
• Interventions: Drug: Suvorexant 20 mg; Drug: Placebo

• Registration Number: NCT04629547
• Lead Sponsor: Washington University School of Medicine

Brief Summary

The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

Detailed Description

This study will investigate if long-term treatment with suvorexant will slow amyloid-β accumulation in the brain. Amyloid-β is a protein involved in the disease process leading to Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of amyloid-beta detected by plasma pT217/T217.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2020-11-09
• Study First Submitted QC: 2020-11-09
• Study First Posted: 2020-11-16
• Study Start: 2022-05-25
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-25
• Last Update Posted: 2024-11-27
• Primary Completion: 2026-05
• Study Completion: 2026-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Male or female.
• Any race or ethnicity.
• Participants must be age ≥65 years and able to sign informed consent.
• Global Clinical Dementia Rating (CDR) 0.
• Willing and able to undergo study procedures.

Read More

Exclusion Criteria

• History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia

• Actigraphic sleep efficiency >85%.

• Abnormal movement of the non-dominant arm (would affect actigraphy data in unpredictable ways).

• STOP-Bang score >6 for participants without PAP

• Untreated OSA with AHI ≥15 on home sleep test

• Treated sleep apnea with PAP non-compliance

  • PAP compliance is defined as >= 4 hours per night >70% of the nights

• Plasma A-beta and tau test with a plasma p-tau 217% ≤0.82

• Stroke.

• Chronic kidney disease defined as patients with markers of kidney damage or eGFR of < 45 ml/min/1.73m2.

• Hepatic impairment defined as AST and/or ALT > 2x upper limit of normal (normal limits AST: 11-47 IU/L, ALT: 6-53 IU/L).

• HIV/AIDS.

• History of substance abuse or alcohol abuse in the proceeding 6 months.

• Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.

• History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.

• Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's discretion:

  • Cardiovascular disease requiring medication except for controlled hypertension.
  • Pulmonary disease.
  • Type I diabetes.
  • Neurologic or psychiatric disorder requiring medication.
  • Tobacco use.
  • Use of sedating medications.
  • Use of medications that interact with suvorexant (if cannot be discontinued)
  • Abnormal safety labs

• History of current suicidal ideations.

• Currently pregnant or breast-feeding.

• In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.

• Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.

• Must not participate in another drug or device study prior to the end of this study participation.

Exclusion criteria for optional lumbar punctures

-• Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Poor sleep treatment group	Suvorexant 20 mg	100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years
Poor sleep control grop	Placebo	100 participants will be randomized to take placebo daily at h.s. for two years.

Primary Outcome Measures

Name	Time	Method
Change from baseline in Amyloid-β accumulation measured by plasma pT217/T217 in participants treated with 20 mg suvorexant compared to placebo	24 months	Blood collection

Secondary Outcome Measures

Name	Time	Method
Change in plasma Amyloid-β compared to placebo	24 months	Blood collection
Change in CSF Amyloid-β compared to placebo	24 months	Cerebrospinal fluid collection
Change in plasma tau compared to placebo	24 months	Blood collection
Change in CSF tau compared to placebo	24 months	Cerebrospinal fluid collection
Change in plasma p-tau compared to placebo	24 months	Blood collection
Change in CSF p-tau compared to placebo	24 months	Cerebrospinal fluid collection
Change in cognitive performance compared to placebo	24 months	Measured by a cognitive composite consisting of the Digit Symbol Substitution Test, Animal Naming, Trails B and the Free and Cued Selective Reminding Test. Each test will be z-scored and then averaged together to make the composite.
Change in transcriptomics compared to placebo	24 months	blood and optional CSF collection
Change in metabolomics compared to placebo	24 months	blood and optional CSF collection
Change in proteomics compared to placebo	24 months	blood and optional CSF collection
Change in gut microbiome compared to placebo	214 months	optional stool sample collection

Trial Locations

Locations (1)

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States